Studying blood and tumor samples from people with chest cancers
Studies samples from blood and tumors in people with thoracic cancers.
Key facts
- Who runs it
- Stanford University
- Where
- Stanford, United StatesSee the site
- Trial code
- Registry title
- Molecular Analysis of Thoracic Malignancies
- Status
- Enrolling by invitation
- People taking part
- 1,000 people, planned
- Started
- Aug 2011
- Expected to end
- Jun 2031
- Type of study
- Observational
- Record updated
- 26 December 2025
Who can take part
AI summary
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for adults with a proven chest cancer, such as lung cancer, thymoma, thymic carcinoma or mesothelioma. It studies blood, tumor tissue and other fluids.
- Age
- 18 years or older
- Sex
- Men and women can join
- Disease stage
- Proven non-small cell lung cancer, small cell lung cancer, thymoma, thymic carcinoma, mesothelioma, or carcinoma of unknown primary consistent with a primary thoracic malignancy
Main reasons for not taking part
- Not able to understand and sign a written informed consent document
- Not willing to sign a written informed consent document
The registry criteria, word for word
Show all 3 criteriaShow less
Who can take part
- 1.Histologically proven diagnosis of non-small cell lung cancer, small cell lung cancer, thymoma, thymic carcinoma, mesothelioma, or carcinoma of unknown primary consistent with the presentation of a primary thoracic malignancy
- 2.18 years of age or older
- 3.Ability to understand and the willingness to sign a written informed consent document
Where in United States
- Stanford University School of MedicineStanford, United StatesEnrolling by invitation
About the trial
What the trial wants to find out
A research study to learn about the biologic features of cancer development, growth, and spread. We are studying components of blood, tumor tissue, normal tissue, and other fluids, such as urine, cerebrospinal fluid, abdominal or chest fluid in patients with cancer. Our analyses of blood, tissue, and/or fluids may lead to improved diagnosis and treatment of cancer by the identification of markers that predict clinical outcome, markers that predict response to specific therapies, and the identification of targets for new therapies.
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorData and sources
- Registry record
- Listed on ClinicalTrials.gov.
- Official title
- Molecular Analysis of Thoracic Malignancies
- Plain-language title
- Studying blood and tumor samples from people with chest cancersGenerated from the registry record. The registry title is the official one.
- AI summary
- From the trial's eligibility criteria. Read by machine on 12 November 2026.
- Record updated
- 26 December 2025